A Shanghai-based company focused on translating microbiome medicine.
About usLuc Rui · Microbiome medicine
From the gut
microbiome,
rethinking treatment.
Luc Rui is a clinical translation platform for microbiome medicine—standardising faecal microbiota transplantation (FMT), supporting research and building the next generation of microbial therapies.
Clinical collaboration / 01
Standardised
Who we are
We believe the microbiome is a vital dimension of human health. Luc Rui connects basic research, standardised preparation and clinical practice to move FMT from experience to reproducible standards.
Since 2012, we have built donor management, preparation quality control, cold-chain logistics and clinical collaboration around FMT—and brought real clinical questions back into research and industrialisation.
Discover Luc RuiA network connecting clinical and industrial resources across China.
Our networkAn FMT industrial base with a total investment of RMB 150 million.
The baseTotal project funding of a national key R&D programme (RMB).
ResearchWhat we do
From a technology,
to a clinical capability.
Standardised preparation, clinical research and an industrial platform work as one system. The question is not only whether something can be done, but whether it can be done consistently, verified and trusted by clinical teams.
01 / Standardised FMTStandardised FMT preparation
From donor screening to vial and capsule preparation, cold chain and full traceability—managed through one quality system.
See the standard
02 / Clinical researchClinical research & evidence
Working with clinical teams to define questions, design studies and accumulate real-world data in a compliant framework.
Explore collaboration
03 / Industrial platformIndustrialisation & quality
A 2,800 m² base, GMP/P2 laboratories and digital quality control provide the infrastructure for scale.
Inside the base
Infrastructure / Quality
A base built for standardisation.
In 2023, Luc Rui, the Bengbu government and Shanghai Tenth People's Hospital co-built an intestinal microbiome and FMT industrial base—bringing donor management, preparation, testing, cold chain and data traceability into one system.
2,800 m²
Industrial base covering preparation, testing and R&D.
RMB 150m
Total project investment, built with public partners.
1m vials / year
Designed annual capacity for clinical supply.
3m capsules / year
Designed annual capacity for oral formats.
Pipeline
From FMT,
to the next generation of microbiome therapies.
Standardised FMT is the starting point, not the destination. We are working across formats, strains and mechanisms to move complex microbial communities toward defined, verifiable products.
Standardised FMT
Donor screening, vial and capsule preparation, cold-chain delivery and traceability.
EstablishedNext-generation 2.0
Continuing optimisation of format, tolerability and clinical usability.
IterationFunctional strains
Moving from complex communities to defined, standardisable strain combinations.
ResearchLive biotherapeutics
Development under pharmaceutical standards, pending mechanism, process and clinical validation.
Long termClinical collaboration
The best evidence
comes from the clinic.
We work with clinical teams to frame questions, design studies and feed every learning back into the standardised system.
Start a collaborationGastrointestinal disease & FMT
Research on the standardised use and mechanisms of FMT in digestive disease.
Autism with co-occurring GI symptoms
Investigator-initiated research focused on GI symptoms, sleep and daily function.
Resistant bacteria & transplant complications
Working with critical care, haematology and transplant teams to explore clinical boundaries.
These are investigator-initiated research directions, not product indications or efficacy claims. FMT must be delivered by qualified healthcare institutions under appropriate indications and informed consent; findings require larger, controlled studies.
News & insights
Progress,
in plain sight.
Company updates, research collaboration and observations on a technology moving from the lab into clinical practice.
Luc Rui joins a national key R&D programme on microbiome transplantation
The project focuses on donor–recipient adaptation, functional components, molecular mechanisms and standardised strain transplantation—exploring a path from heterogeneous FMT to defined strain combinations.
Read the updateContact
Start a conversation.
Shanghai headquarters
China · Shanghai
Corporate, clinical and business teams
Bengbu industrial base
Anhui · China
Microbiome and FMT industrial base
Clinical, research & media
Use the form to reach the relevant team.
What are you looking for?
Tell us a little about your organisation and the conversation you would like to have. This is a design prototype—no data is sent or stored.
